# Trading Delayed in Newest Addition to Tel Aviv Flagship Indices

*At the company’s request, trading in biomedical company Alpha Tau will open today on the Tel Aviv Stock Exchange (TASE) alongside Nasdaq • An hour before the opening, the company will present investors with interim results from a brain cancer trial • Last month, the FDA approved the trial’s expansion*

- Published: 2026-11-16T09:59:18.703Z (Monday, November 16, 2026)
- Updated: 2026-11-16T10:03:22.387Z
- By: Sharon Birkman
- Section: TASE Stocks
- Canonical: https://tv10.news/news/capital-market/tase-stocks/127306/trading-delayed-in-new-tel-aviv-flagship-index-addition/
- Hebrew original (TV10): https://tv10.co.il/news/capital-market/tel-aviv-stocks/127306/
- Publisher: TV10 Global (TV10, Israel’s economic channel). Translated from Hebrew with AI and an automated accuracy check.

Only this month, [Alpha Tau Medical joined the](https://tv10.co.il/articles/עדכון-מדדים-סוער-בתל-אביב-עליות-קלות-בנ) TA-90 and TA-125 indices, and today (Monday) the company asked [to delay the opening of trading in its shares](https://tv10.news/news/capital-market/tase-stocks/127302/mixed-trading-week-dual-listed-stocks-weigh/) on the Tel Aviv Stock Exchange (TASE) until 16:30, when trading opens on Nasdaq. This follows the release of a material immediate report. Alpha Tau yesterday published interim results from a trial in recurrent glioblastoma and will hold an investor call today at 15:30 Israel time to present the findings.

![Medicine, illustration](https://tv10.news/media/2026/11/66/66d17638dad73239bbf90710ed3385a05b521538c42e661f9c73540a02543959.jpg)

Medicine, illustration | Photo: Shutterstock

[The company will hold an investor call](https://tv10.co.il/news/israel/health/126036/) today at 15:30 Israel time, an hour before trading in the stock opens. During the call, company management and Dr. Joshua Palmer of The Ohio State University, the lead investigator in the REGAIN trial it conducted on brain cancer patients, will present the interim results unveiled at a neuro-oncology conference in Philadelphia.

Alpha Tau was founded in 2016 and began trading on Nasdaq in 2022 after merging with a SPAC. In August this year, it also began trading in Tel Aviv, without raising capital as part of the listing. The company’s CEO, Uzi Sofer, said at the time that interest among Israeli investors had increased and that some had asked to invest in shekels or through the local indices. In the TASE’s latest index update earlier this month, Alpha Tau entered the TA-90 and TA-125 and became one of three biomedical companies in the TA-125.

Alph

![U.S. Food and Drug Administration (FDA)](https://tv10.news/media/2026/11/31/319781657fc6076883086945b604d6ef3cc85061166e6ccd49fb6f8e487d67eb.jpg)

U.S. Food and Drug Administration (FDA) | Photo: Shutterstock

The company is developing a treatment based on inserting tiny sources of alpha radiation directly into the tumor. The technology, developed at Tel Aviv University, is designed to concentrate the radiation in the tumor and reduce exposure to the surrounding healthy tissue. The REGAIN trial was conducted in the U.S. among patients with glioblastoma, a malignant brain tumor that had recurred after previous radiation treatment and could not be surgically removed. According to an update presented by the company at a neuro-oncology conference in Philadelphia, all eight patients treated in the trial were alive as of November 11, while six had already reached the MRI response assessment stage. Five of them had no measurable tumor remaining at the treated site, a finding classified as a complete response. Last month, the company received FDA approval to expand the treatment trial to 20 patients.

The trial results could also affect Oramed Pharmaceuticals, the biotechnology company that holds about 17% of Alpha Tau. Oramed invested about $38.2 million in purchasing the shares, and at the end of September, the carrying value of the investment, including warrants, was about $252 million. In the first nine months of the year, Oramed recorded revaluation gains of about $174.5 million on the investment.
